Monitoring of tumor glucose utilization by [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) was implemented for the early prediction of treatment response to EGFR-TKIs in NSCLC (26, 43). The gene discussed is EGFR; the disease is neoplasm.